{"id":206632,"name":"OMEROS CORPORATION","slug":"omeros-corporation","state":"WA","country":"United States of America","description":"Biopharmaceutical company focused on small-molecule and protein therapeutics.","totalSpending":765000,"filings":21,"yearlySpending":[{"year":2020,"income":45000},{"year":2021,"income":135000},{"year":2022,"income":180000},{"year":2023,"income":180000},{"year":2024,"income":180000},{"year":2025,"income":45000}],"issues":[{"code":"MMM","display":"Medicare/Medicaid"}],"firms":["GRAYROBINSON PA"],"lobbyists":["DOYLE BARTLETT","CHRISTOPHER MCCANNELL","KEENAN HALE"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Executive Office of the President (EOP)"],"sampleDescriptions":["Issues related to medicare reimbursement.\nReimbursement classification of OMIDRIA.\nMonitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System and Ambu","Issues related to Medicare reimbursement. \nReimbursement classification of OMIDRIA. Monitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System and Amb","Issues related to Medicare reimbursement. \nReimbursement classification of OMIDRIA. Monitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System and Amb","Issues related to Medicare reimbursement.\nReimbursement classification of OMIDRIA. Monitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System and Ambu","Issues related to Medicare reimbursement.\nReimbursement classification of OMIDRIA. Monitor Medicare reimbursement for ophthalmic drugs under the Hospital Outpatient Prospective Payment System and Ambu"]}